Position of the Transparency Council – Jardiance (empagliflozin)
At its meeting on 16 December 2024, the Transparency Council adopted position No. 146/2024 on the evaluation of the drug Jardiance (empagliflozin) for the indication of chronic heart failure in adult patients.